FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

In this Healio Video Perspective from the Congress on Controversies in Ophthalmology, Lloyd Clark, MD, discusses sustained ...

Pelthos Therapeutics, a Durham-based wholly owned subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND), is combining with ...

People are not born allergic to things, but they can be born with a genetic tendency to become allergic to things to which ...

Quarterly business operating income, excluding one-off items, rose 20.1% to 2.90 billion euros ($3.29 billion), surpassing the average analyst estimate of 2.68 billion euros. The company reported net ...

Learn more about whether LeMaitre Vascular, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over ...